ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Buffy-coat-derived megakaryocytes for monoclonal antibody immobilization of platelet antigens (MAIMA) assay

1Center for Clinical Transfusion Medicine, Tuebingen, Baden-Wurttemberg, Germany, 2Department of Transfusion Medicine, Cellular Therapeutics and Hemostaseology, Clinic for Anesthesiology LMU University Hospital, Munich, Baden-Wurttemberg, Germany, 3Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany, Tuebingen, Baden-Wurttemberg, Germany, 4Institute for Clinical and Experimental Tranfusion Medicine, Tuebingen, Baden-Wurttemberg, Germany, 5Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giesen, Niedersachsen, Germany, 6Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen, University Hospital of Tuebingen, Tuebingen, Germany, Tübingen, Baden-Wurttemberg, Germany

Abstract Number: PB1110

Meeting: ISTH 2022 Congress

Theme: Diagnostics and OMICs » Laboratory Diagnostics

Background: Serologic detection and characterization of anti-human platelet antigen (HPA) antibodies are essential for proper diagnosis and treatment in fetal and neonatal immune thrombocytopenia. The monoclonal antibody immobilization of platelet antigens (MAIPA) assay is the standard assay for the detection of anti-HPA antibodies. For this assay, fresh platelets from HPA-genotyped donors are required, which is a limitation for laboratories with no direct access to blood donors.

Aims: In the current study, the use of buffy coat-derived, in-vitro cultured megakaryocytes (MKs) instead of donor-derived platelets in MAIPA for the determination of anti-HPA antibodies was investigated.

Methods: We isolated CD34+ cells from buffy coats of blood donors using magnetic beads. CD34+ cells were differentiated for 28 days in vitro into megakaryocytes. Megakaryocyte cell lines were characterized with flow cytometry using CD41, CD61, CD42a and CD42d expression and DNA content. The performance of MAIPA with megakaryocytes was assessed using WHO reference sera und patients’ sera with well-characterized anti-HPA antibodies.

Results: Testing WHO standard sera in MAIPA with megakaryocytes (MAIMA) revealed similar reaction compared to standard MAIPA using platelets (OD HPA 1a:0.51±0.13 vs. 0.52±0.20, p=0.99 and OD for HPA5b (0.15±0.09 vs. 0.25±0.07, p=0.40, Figure 1). However, OD amplitudes were significantly lower in MAIMA than in MAIPA with donor platelets for HPA 3a (0.19±0.03 vs. 0.53±0.07, p=0.02, Figure 1). OD amplitudes were similar with megakaryocytes and platelets in MAIPA using patients’ sera with anti-HPA-1a and anti-HPA 5b antibodies (Figure 2).

Conclusion(s): Buffy-coat-derived megakaryocytes have the potential to replace donor platelets in MAIPA in the future. Further studies are needed for standardization and validation of this technique in routine laboratories.

Figure 1

Optical density measurements in MAIPA and MAIMA with WHO standard reagents

Figure 2

Optical density measurements in MAIPA and MAIMA with patient sera

To cite this abstract in AMA style:

Uzun G, Lucic J, Althaus K, Rigoni F, Lyshy F, Nowak-Harnau S, Marini I, Sachs U, Backchoul T. Buffy-coat-derived megakaryocytes for monoclonal antibody immobilization of platelet antigens (MAIMA) assay [abstract]. https://abstracts.isth.org/abstract/buffy-coat-derived-megakaryocytes-for-monoclonal-antibody-immobilization-of-platelet-antigens-maima-assay/. Accessed November 30, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/buffy-coat-derived-megakaryocytes-for-monoclonal-antibody-immobilization-of-platelet-antigens-maima-assay/